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Characterisation of Novel Molecular Mechanisms Involved in Anthracycline-
Induced Cardiotoxicity  
Recent advances in cancer treatment have improved cancer survivorship; however as a result the 
incidence of cancer therapy induced cardiotoxicity has increased. This major complication can 
present both as an acute toxicity or a chronic toxicity and can impose substantial detriment to both 
the quality of life and survival of patients. Consequently, greater understanding of the molecular 
mechanisms responsible for these toxicities, and identification of therapeutic strategies to mitigate 
and overcome these toxicities are significantly important. Recently, clinical studies have 
demonstrated that administration of drugs that act upon the angiotensin system may reduce the 
cardiotoxicity of anthracyclines. However, despite showing promise, the molecular mechanisms 
responsible for toxicity mitigation are currently unknown. This study has utilised a variety of human 
cardiomyocyte in vitro models and real-time impedance-based cell analyses (xCELLigence 
technology) to demonstrate induction of cardiomyocyte hypertrophy by doxorubicin, and through its 
reduction by blockade of the angiotensin pathway, implicates synergism between doxorubicin-
mediated toxicity and angiotensin signalling in cardiomyocytes. Beat characteristics of iPSC derived 
cardiomyocytes have also been assessed using xCELLigence Cardio technology during exposure to 
doxorubicin alone and during angiotensin blockade in an attempt to elucidate the effects of 
cardiomyocyte hypertrophy on contractility of these cells. The methodologies used in this study 
offer a robust clinically relevant model for assessing drug-induced cardiotoxicity, with the study 
identifying a novel mechanism for anthracycline-induced cardiotoxicity. 
